The Johnson and Johnson EGFR-MET combination therapy was approved for a clinical trial of oxytinib-resistant NSCLC.

Recently, Johnson and Johnson Amivantamab (EGFR-MET dual resistance and Lazertinib (third generation EGFR-TKI) were approved in China for 2 clinical trials, respectively: 1) joint treatment of EGFR 19 exon loss or L858R activation mutation, without previous treatment of local late stage or progressive NSCLC patients; 2) joint drug treatment EGFR No. 19 exons are missing or L858R-activated mutations, and NSCLC patients with disease progression after the use of first-generation (e.g., erotinib, giffeitinib, etc.) or second-generation (e.g. afatinib, dachtinib, etc.) TKI or third-generation TKI (e.g., oseltinib) for first- or second-line treatment.
Amivantamab and Lazertinib are the "stars" of the just-concluded ESMO2020 conference, a Phase I clinical study code-named CHRYSALIS (NCT0260977) 6) The results showed that the two drugs were used in a combined treatment of NSCLC patients with EGFR 19Del or L858R mutations, with ANR reaching 100% and ORR reaching 36% for patients with oghithyni resistance.
CHRYSALIS study was divided into dose exploration and amplification queues, and after entering the amplification queue, patients were divided into the osexitinib resistance group (n-45) and the EGFR primary treatment group (n-20).
results reported at the ESMO conference showed that the amivantamab-Lazertinib drug was 100% ORR for 20 EGFR primary patients, including 20 PR patients.
follow-up time and the medium treatment time of 7 months, mDOR has not yet arrived.
of the 45 patients who were drug-resistant with Oxitinib, amivantamab and Lazertinib combined orR reached 36%, including 1 case of CR, 15 cases of PR;
Amivantamab-Lazertinib combined treatment is safe and well-to-bear, and common adverse reactions are rash, infusion reaction, meth, hypoproteinemia, etc.
, the Amivantamab-Lazertinib Joint Programme has conducted Phase III MARIPOSA studies to assess the efficacy and safety of the joint programme compared to Oghitinib's treatment of EGFR mutation NSCLC.
.